A biotechnology company developing stem cell therapies to treat neurodegenerative diseases
Our proprietary technology converts mesenchymal stem cells into NurOwn®, a biological drug delivery system designed to support damaged neurons
NurOwn® cells dampen the immune system and secrete growth factors that help damaged neurons survive.
BrainStorm Cell Therapeutics (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s Disease (PD).
November 7, 2018BrainStorm Cell Therapeutics to Present at November Clinical and Investor Conferences
October 29, 2018BrainStorm Announces Financial Results for the Third Quarter of 2018 and Provides a Corporate Update
October 17, 2018BrainStorm to Announce Third Quarter Financial Results and Provide Corporate Update on Monday, October 29
BrainStorm is proceeding with a randomized, double-blind, placebo-controlled multi-dose Phase 3 trial that is being conducted at multiple U.S. sites.
For more information on enrollment, contact one of the participating clinical trial sites.
Additional information can be found on clinicaltrials.gov under identifier (NCT number): NCT03280056.